Maria Laura Bolognesi

List of Publications by Year in Descending Order

171 papers	7,395 citations	46 h-index	80 g-index
198 ext. papers	8,376 ext. citations	6.1 avg, IF	6.1 L-index

#	Paper	IF	Citations
171	Therapeutic strategies for identifying small molecules against prion diseases.. *Cell and Tissue Research*, **2022**, 1	4.2	2
170	From combinations to multitarget-directed ligands: A continuum in Alzheimer's disease polypharmacology. *Medicinal Research Reviews*, **2021**, 41, 2606-2633	14.4	41
169	New Biomass Reagents for the Synthesis of Bioactive Compounds. *Topics in Medicinal Chemistry*, **2021**, 373-389	0.4	
168	Sustainable Drug Discovery of Multi-Target-Directed Ligands for Alzheimer's Disease. *Journal of Medicinal Chemistry*, **2021**, 64, 4972-4990	8.3	18
167	Phenothiazine-Tacrine Heterodimers: Pursuing Multitarget Directed Approach in Alzheimer's Disease. *ACS Chemical Neuroscience*, **2021**, 12, 1698-1715	5.7	1
166	Design and In Vitro Study of a Dual Drug-Loaded Delivery System Produced by Electrospinning for the Treatment of Acute Injuries of the Central Nervous System. *Pharmaceutics*, **2021**, 13,	6.4	2
165	Turning Donepezil into a Multi-Target-Directed Ligand through a Merging Strategy. *ChemMedChem*, **2021**, 16, 187-198	3.7	4
164	Design and synthesis of nature-inspired chromenopyrroles as potential modulators of mitochondrial metabolism. *Medicinal Chemistry Research*, **2021**, 30, 635-646	2.2	
163	Discovery of sustainable drugs for Alzheimer's disease: cardanol-derived cholinesterase inhibitors with antioxidant and anti-amyloid properties. *RSC Medicinal Chemistry*, **2021**, 12, 1154-1163	3.5	0
162	Sustainable production of pharmaceutical, nutraceutical and bioactive compounds from biomass and waste. *Chemical Society Reviews*, **2021**, 50, 11191-11207	58.5	23
161	From virtual screening hits targeting a cryptic pocket in BACE-1 to a nontoxic brain permeable multitarget anti-Alzheimer lead with disease-modifying and cognition-enhancing effects. *European Journal of Medicinal Chemistry*, **2021**, 225, 113779	6.8	3
160	N-1,2,3-triazole-isatin derivatives for cholinesterase and β-amyloid aggregation inhibition: A comprehensive bioassay study. *Bioorganic Chemistry*, **2020**, 98, 103753	5.1	16
159	A Different Kind of Medicinal Chemistry Toolbox. *ACS Medicinal Chemistry Letters*, **2020**, 11, 245-248	4.3	0
158	Histone deacetylases as targets for the treatment of neurodegenerative disorders: Challenges and future opportunities. *Medicinal Research Reviews*, **2020**, 40, 2177-2211	14.4	16
157	In silico/in-vitro screening and hit evaluation identified new phenothiazine anti-prion derivatives. *European Journal of Medicinal Chemistry*, **2020**, 196, 112295	6.8	3
156	Identification of a 2,4-diaminopyrimidine scaffold targeting Trypanosoma brucei pteridine reductase 1 from the LIBRA compound library screening campaign. *European Journal of Medicinal Chemistry*, **2020**, 189, 112047	6.8	3
155	Stereocontrolled transformations of cyclohexadienone derivatives to access stereochemically rich and natural product-inspired architectures. *Organic and Biomolecular Chemistry*, **2020**, 18, 8526-8571	3.9	17

154	-Linolenic Acid-Valproic Acid Conjugates: Toward Single-Molecule Polypharmacology for Multiple Sclerosis. *ACS Medicinal Chemistry Letters*, **2020**, 11, 2406-2413	4.3	2
153	Discovery of Sustainable Drugs for Neglected Tropical Diseases: Cashew Nut Shell Liquid (CNSL)-Based Hybrids Target Mitochondrial Function and ATP Production in Trypanosoma brucei. *ChemMedChem*, **2019**, 14, 621-635	3.7	14
152	Structure-activity relationships and mechanistic studies of novel mitochondria-targeted, leishmanicidal derivatives of the 4-aminostyrylquinoline scaffold. *European Journal of Medicinal Chemistry*, **2019**, 171, 38-53	6.8	8
151	Novel Sustainable-by-Design HDAC Inhibitors for the Treatment of Alzheimer's Disease. *ACS Medicinal Chemistry Letters*, **2019**, 10, 671-676	4.3	10
150	Accelerating Drug Discovery Efforts for Trypanosomatidic Infections Using an Integrated Transnational Academic Drug Discovery Platform. *SLAS Discovery*, **2019**, 24, 346-361	3.4	9
149	Novel tacrine-tryptophan hybrids: Multi-target directed ligands as potential treatment for Alzheimer's disease. *European Journal of Medicinal Chemistry*, **2019**, 168, 491-514	6.8	49
148	Novel multi target-directed ligands targeting 5-HT receptors with in cellulo antioxidant properties as promising leads in Alzheimer's disease. *European Journal of Medicinal Chemistry*, **2019**, 182, 111596	6.8	8
147	Tacrine-O-protected phenolics heterodimers as multitarget-directed ligands against Alzheimer's disease: Selective subnanomolar BuChE inhibitors. *European Journal of Medicinal Chemistry*, **2019**, 181, 111550	6.8	13
146	Novel screening approaches for human prion diseases drug discovery. *Expert Opinion on Drug Discovery*, **2019**, 14, 983-993	6.2	4
145	Molecular Hybridization as a Tool for Designing Multitarget Drug Candidates for Complex Diseases. *Current Topics in Medicinal Chemistry*, **2019**, 19, 1694-1711	3	76
144	Sustainable anti-trypanosomatid drugs: An aspirational goal for medicinal chemistry. *Annual Reports in Medicinal Chemistry*, **2019**, 153-176	1.6	1
143	A Focused Library of Psychotropic Analogues with Neuroprotective and Neuroregenerative Potential. *ACS Chemical Neuroscience*, **2019**, 10, 279-294	5.7	14
142	Development of a Focused Library of Triazole-Linked Privileged-Structure-Based Conjugates Leading to the Discovery of Novel Phenotypic Hits against Protozoan Parasitic Infections. *ChemMedChem*, **2018**, 13, 678-683	3.7	11
141	BACE-1 Inhibitors: From Recent Single-Target Molecules to Multitarget Compounds for Alzheimer's Disease. *Journal of Medicinal Chemistry*, **2018**, 61, 619-637	8.3	66
140	Tacripyrimidines, the first tacrine-dihydropyrimidine hybrids, as multi-target-directed ligands for Alzheimer's disease. *European Journal of Medicinal Chemistry*, **2018**, 155, 839-846	6.8	30
139	Tau-Centric Multitarget Approach for Alzheimer's Disease: Development of First-in-Class Dual Glycogen Synthase Kinase 3 and Tau-Aggregation Inhibitors. *Journal of Medicinal Chemistry*, **2018**, 61, 7640-7656	8.3	53
138	The Mu.Ta.Lig. Chemotheca: A Community-Populated Molecular Database for Multi-Target Ligands Identification and Compound-Repurposing. *Frontiers in Chemistry*, **2018**, 6, 130	5	6
137	A perspective on multi-target drug discovery and design for complex diseases. *Clinical and Translational Medicine*, **2018**, 7, 3	5.7	307

136	Repurposing of Drugs Targeting YAP-TEAD Functions. *Cancers*, **2018**, 10,	6.6	18
135	Molecular basis for covalent inhibition of glyceraldehyde-3-phosphate dehydrogenase by a 2-phenoxy-1,4-naphthoquinone small molecule. *Chemical Biology and Drug Design*, **2017**, 90, 225-235	2.9	12
134	Neurodegenerative drug discovery: building on the past, looking to the future. *Future Medicinal Chemistry*, **2017**, 9, 707-709	4.1	10
133	Tacrine-resveratrol fused hybrids as multi-target-directed ligands against Alzheimer's disease. *European Journal of Medicinal Chemistry*, **2017**, 127, 250-262	6.8	74
132	Crassiflorone derivatives that inhibit Trypanosoma brucei glyceraldehyde-3-phosphate dehydrogenase (TbGAPDH) and Trypanosoma cruzi trypanothione reductase (TcTR) and display trypanocidal activity. *European Journal of Medicinal Chemistry*, **2017**, 141, 138-148	6.8	17
131	Therapeutic Approaches to Prion Diseases. *Progress in Molecular Biology and Translational Science*, **2017**, 150, 433-453	4	6
130	Drug Discovery Strategies for the Generation of Multitarget Ligands against Neglected Tropical Diseases. *Methods and Principles in Medicinal Chemistry*, **2017**, 135-159	0.4	
129	New tacrine dimers with antioxidant linkers as dual drugs: Anti-Alzheimer's and antiproliferative agents. *European Journal of Medicinal Chemistry*, **2017**, 138, 761-773	6.8	38
128	Neuroregeneration versus neurodegeneration: toward a paradigm shift in Alzheimer's disease drug discovery. *Future Medicinal Chemistry*, **2017**, 9, 995-1013	4.1	14
127	Medicinal Chemistry of Hybrids for Neurodegenerative Diseases **2017**, 259-277		3
126	Trypanocidal Activity of Quinoxaline 1,4 Di-N-oxide Derivatives as Trypanothione Reductase Inhibitors. *Molecules*, **2017**, 22,	4.8	20
125	Design, Synthesis and Structure-Activity Relationships of a Phenotypic Small Library against Protozoan Infections. *Proceedings (mdpi)*, **2017**, 1, 648	0.3	2
124	Sustainable Multi-Target Drugs for Neglected Tropical Diseases Caused by Trypanosomatids: Dream or Reality?. *Proceedings (mdpi)*, **2017**, 1, 664	0.3	
123	Nutritional and Pharmacological Strategies to Regulate Microglial Polarization in Cognitive Aging and Alzheimer's Disease. *Frontiers in Aging Neuroscience*, **2017**, 9, 175	5.3	27
122	Cardanol-derived AChE inhibitors: Towards the development of dual binding derivatives for Alzheimer's disease. *European Journal of Medicinal Chemistry*, **2016**, 108, 687-700	6.8	66
121	Changing paradigm to target microglia in neurodegenerative diseases: from anti-inflammatory strategy to active immunomodulation. *Expert Opinion on Therapeutic Targets*, **2016**, 20, 627-40	6.4	40
120	Navigating the Chemical Space of Multitarget-Directed Ligands: From Hybrids to Fragments in Alzheimer's Disease. *Molecules*, **2016**, 21, 466	4.8	64
119	Novel 8-Hydroxyquinoline Derivatives as Multitarget Compounds for the Treatment of Alzheimer's Disease. *ChemMedChem*, **2016**, 11, 1284-95	3.7	59

118	Synthesis and structure-activity relationships of novel arylpiperazines as potent antagonists of 1-adrenoceptor. *European Journal of Medicinal Chemistry*, **2016**, 122, 601-610	6.8	3
117	From Companion Diagnostics to Theranostics: A New Avenue for Alzheimer's Disease?. *Journal of Medicinal Chemistry*, **2016**, 59, 7759-70	8.3	31
116	2-Phenoxy-1,4-naphthoquinones: From a Multitarget Antitrypanosomal to a Potential Antitumor Profile. *Journal of Medicinal Chemistry*, **2015**, 58, 6422-34	8.3	35
115	3,4-Dihydro-1,3,5-triazin-2(1H)-ones as the First Dual BACE-1/GSK-3 Fragment Hits against Alzheimer's Disease. *ACS Chemical Neuroscience*, **2015**, 6, 1665-82	5.7	47
114	Presynaptic M3 muscarinic cholinoceptors mediate inhibition of excitatory synaptic transmission in area CA1 of rat hippocampus. *Brain Research*, **2015**, 1629, 260-9	3.7	9
113	Rational approach to an antiprion compound with a multiple mechanism of action. *Future Medicinal Chemistry*, **2015**, 7, 2113-20	4.1	8
112	Novel tacrine-grafted Ugi adducts as multipotent anti-Alzheimer drugs: a synthetic renewal in tacrine-ferulic acid hybrids. *ChemMedChem*, **2015**, 10, 523-39	3.7	56
111	Lewis Acid-Catalyzed Generation of C?C and C?N Bonds on Deficient Heterocyclic Substrates. *Advanced Synthesis and Catalysis*, **2015**, 357, 185-195	5.6	18
110	Multitarget drug discovery for Alzheimer's disease: triazinones as BACE-1 and GSK-3 inhibitors. *Angewandte Chemie - International Edition*, **2015**, 54, 1578-82	16.4	87
109	The Hippo Pathway and YAP/TAZ-TEAD Protein-Protein Interaction as Targets for Regenerative Medicine and Cancer Treatment. *Journal of Medicinal Chemistry*, **2015**, 58, 4857-73	8.3	109
108	Approaches for discovering anti-prion compounds: lessons learned and challenges ahead. *Expert Opinion on Drug Discovery*, **2015**, 10, 389-97	6.2	23
107	Multitarget Drug Discovery for Alzheimer's Disease: Triazinones as BACE-1 and GSK-3 Inhibitors. *Angewandte Chemie*, **2015**, 127, 1598-1602	3.6	5
106	Imaging of amyloid plaques by near infrared fluorescent tracers: a new frontier for chemical neuroscience. *Chemical Society Reviews*, **2015**, 44, 1807-19	58.5	116
105	Tackling Neurodegeneration with Multi-target and Theranostic Small Molecules. *Medicinal Chemistry Reviews*, **2015**, 347-356	0.1	2
104	Toward the development of dual-targeted glyceraldehyde-3-phosphate dehydrogenase/trypanothione reductase inhibitors against Trypanosoma brucei and Trypanosoma cruzi. *ChemMedChem*, **2014**, 9, 371-82	3.7	39
103	Two diseases, one approach: multitarget drug discovery in Alzheimer's and neglected tropical diseases. *MedChemComm*, **2014**, 5, 853-861	5	56
102	Multitarget drug design strategy: quinone-tacrine hybrids designed to block amyloid- aggregation and to exert anticholinesterase and antioxidant effects. *Journal of Medicinal Chemistry*, **2014**, 57, 8576-89	8.3	122
101	Synthesis of new lipoic acid conjugates and evaluation of their free radical scavenging and neuroprotective activities. *Chemical Biology and Drug Design*, **2014**, 83, 688-96	2.9	8

100	Multitarget ligands and theranostics: sharpening the medicinal chemistry sword against prion diseases. *Future Medicinal Chemistry*, **2014**, 6, 1017-29	4.1	7
99	Quinone-amino acid conjugates targeting Leishmania amino acid transporters. *PLoS ONE*, **2014**, 9, e107994	3.7	12
98	The bivalent ligand approach as a tool for improving the in vitro anti-Alzheimer multitarget profile of dimebon. *ChemMedChem*, **2013**, 8, 1276-81	3.7	26
97	Quinones bearing non-steroidal anti-inflammatory fragments as multitarget ligands for Alzheimer's disease. *Bioorganic and Medicinal Chemistry Letters*, **2013**, 23, 6254-8	2.9	17
96	Design, synthesis, and biological and crystallographic evaluation of novel inhibitors of Plasmodium falciparum enoyl-ACP-reductase (PfFabI). *Journal of Medicinal Chemistry*, **2013**, 56, 7516-26	8.3	26
95	A Fluorescent Styrylquinoline with Combined Therapeutic and Diagnostic Activities against Alzheimer's and Prion Diseases. *ACS Medicinal Chemistry Letters*, **2013**, 4, 225-9	4.3	36
94	Solvent- and chromatography-free amination of □deficient nitrogen heterocycles under microwave irradiation. A fast, efficient and green route to 9-aminoacridines, 4-aminoquinolines and 4-aminoquinazolines and its application to the synthesis of the drugs amsacrine and bistacrine. *Tetrahedron*, **2013**, 69, 1024-1030	2.4	12
93	Amyloid Chemical Probes and Theranostics: Steps Toward Personalized Medicine in Neurodegenerative Diseases. *Methods and Principles in Medicinal Chemistry*, **2013**, 211-226	0.4	3
92	Small-molecule theranostic probes: a promising future in neurodegenerative diseases. *International Journal of Cell Biology*, **2013**, 2013, 150952	2.6	29
91	Naphthoquinone derivatives exert their antitrypanosomal activity via a multi-target mechanism. *PLoS Neglected Tropical Diseases*, **2013**, 7, e2012	4.8	46
90	Pharmacological characterization of memoquin, a multi-target compound for the treatment of Alzheimer's disease. *PLoS ONE*, **2013**, 8, e56870	3.7	62
89	Modulation of prion by small molecules: from monovalent to bivalent and multivalent ligands. *Current Topics in Medicinal Chemistry*, **2013**, 13, 2491-503	3	9
88	Multifunctional tacrine derivatives in Alzheimer's disease. *Current Topics in Medicinal Chemistry*, **2013**, 13, 1771-86	3	71
87	A small chemical library of 2-aminoimidazole derivatives as BACE-1 inhibitors: Structure-based design, synthesis, and biological evaluation. *European Journal of Medicinal Chemistry*, **2012**, 48, 206-13	6.8	22
86	Chapter 18:Discovery of Multi-Target Agents for Neurological Diseases via Ligand Design. *RSC Drug Discovery Series*, **2012**, 290-315	0.6	3
85	Conjugation of quinones with natural polyamines: toward an expanded antitrypanosomatid profile. *Journal of Medicinal Chemistry*, **2012**, 55, 10490-500	8.3	31
84	The modulatory role of M2 muscarinic receptor on apomorphine-induced yawning and genital grooming. *Neuroscience Letters*, **2012**, 531, 91-5	3.3	6
83	Multitargeted Drugs for Treatment of Alzheimer's Disease **2012**, 441-458		5

82	Cystamine-tacrine dimer: a new multi-target-directed ligand as potential therapeutic agent for Alzheimer's disease treatment. *Neuropharmacology*, **2012**, 62, 997-1003	5.5	70
81	Synthesis of monomeric derivatives to probe memoquin's bivalent interactions. *Journal of Medicinal Chemistry*, **2011**, 54, 8299-304	8.3	22
80	The concept of privileged structures in rational drug design: focus on acridine and quinoline scaffolds in neurodegenerative and protozoan diseases. *Expert Opinion on Drug Discovery*, **2011**, 6, 251-68	6.2	63
79	Multi-target-directed ligands as innovative tools to combat trypanosomatid diseases. *Current Topics in Medicinal Chemistry*, **2011**, 11, 2824-33	3	12
78	Sequential virtual screening approach to the identification of small organic molecules as potential BACE-1 inhibitors. *Chemical Biology and Drug Design*, **2011**, 77, 268-71	2.9	12
77	Exploiting the lipoic acid structure in the search for novel multitarget ligands against Alzheimer's disease. *European Journal of Medicinal Chemistry*, **2011**, 46, 5435-42	6.8	71
76	Hybrid lipoic acid derivatives to attack prion disease on multiple fronts. *ChemMedChem*, **2011**, 6, 601-5	3.7	10
75	Remembering Marie Curie's legacy. *ChemMedChem*, **2011**, 6, 575-7	3.7	0
74	Multitargeted drugs discovery: balancing anti-amyloid and anticholinesterase capacity in a single chemical entity. *Bioorganic and Medicinal Chemistry Letters*, **2011**, 21, 2655-8	2.9	55
73	Multitarget-directed ligands: innovative chemical probes and therapeutic tools against Alzheimer's disease. *Current Topics in Medicinal Chemistry*, **2011**, 11, 2797-806	3	29
72	A General Protocol for the Solvent- and Catalyst-Free Synthesis of 2-Styrylquinolines under Focused Microwave Irradiation. *Synlett*, **2011**, 2011, 2577-2579	2.2	2
71	Complementary medicinal chemistry-driven strategies toward new antitrypanosomal and antileishmanial lead drug candidates. *FEMS Immunology and Medical Microbiology*, **2010**, 58, 51-60		27
70	Tacrine derivatives and Alzheimer's disease. *Current Medicinal Chemistry*, **2010**, 17, 1825-38	4.3	180
69	Parallel synthesis, evaluation, and preliminary structure-activity relationship of 2,5-diamino-1,4-benzoquinones as a novel class of bivalent anti-prion compound. *Journal of Medicinal Chemistry*, **2010**, 53, 8197-201	8.3	30
68	Polyamine conjugation of curcumin analogues toward the discovery of mitochondria-directed neuroprotective agents. *Journal of Medicinal Chemistry*, **2010**, 53, 7264-8	8.3	32
67	Polyamines in drug discovery: from the universal template approach to the multitarget-directed ligand design strategy. *Journal of Medicinal Chemistry*, **2010**, 53, 5906-14	8.3	44
66	Synthetic polyamines: an overview of their multiple biological activities. *Amino Acids*, **2010**, 38, 383-92	3.5	20
65	Bis(7)-tacrine derivatives as multitarget-directed ligands: Focus on anticholinesterase and antiamyloid activities. *ChemMedChem*, **2010**, 5, 1215-20	3.7	35

64	Discovery of a class of diketopiperazines as antiprion compounds. *ChemMedChem*, **2010**, 5, 1324-34	3.7	34
63	Synthesis and evaluation of a library of 2,5-bisdiamino-benzoquinone derivatives as probes to modulate protein-protein interactions in prions. *Bioorganic and Medicinal Chemistry Letters*, **2010**, 20, 1866-8	2.9	16
62	Investigation of the photostability properties of memoquin, a quinone derivative for the treatment of Alzheimer's disease. *Journal of Pharmaceutical and Biomedical Analysis*, **2009**, 50, 164-70	3.5	5
61	Memoquin: a multi-target-directed ligand as an innovative therapeutic opportunity for Alzheimer's disease. *Neurotherapeutics*, **2009**, 6, 152-62	6.4	101
60	Privileged structure-guided synthesis of quinazoline derivatives as inhibitors of trypanothione reductase. *Bioorganic and Medicinal Chemistry Letters*, **2009**, 19, 3031-5	2.9	34
59	Alzheimer's disease: new approaches to drug discovery. *Current Opinion in Chemical Biology*, **2009**, 13, 303-8	9.7	100
58	Structure-activity relationships of memoquin: Influence of the chain chirality in the multi-target mechanism of action. *Bioorganic and Medicinal Chemistry Letters*, **2009**, 19, 4312-5	2.9	22
57	Docking Ligands on Protein Surfaces: The Case Study of Prion Protein. *Journal of Chemical Theory and Computation*, **2009**, 5, 2565-73	6.4	30
56	Neglected tropical diseases: multi-target-directed ligands in the search for novel lead candidates against Trypanosoma and Leishmania. *Journal of Medicinal Chemistry*, **2009**, 52, 7339-59	8.3	179
55	Toward a rational design of multitarget-directed antioxidants: merging memoquin and lipoic acid molecular frameworks. *Journal of Medicinal Chemistry*, **2009**, 52, 7883-6	8.3	62
54	MTDL design strategy in the context of Alzheimer's disease: from lipocrine to memoquin and beyond. *Current Pharmaceutical Design*, **2009**, 15, 601-13	3.3	64
53	Progress in acetylcholinesterase inhibitors for Alzheimer's disease: an update. *Expert Opinion on Therapeutic Patents*, **2008**, 18, 387-401	6.8	24
52	Structure-activity relationships of acetylcholinesterase noncovalent inhibitors based on a polyamine backbone. 4. Further investigation on the inner spacer. *Journal of Medicinal Chemistry*, **2008**, 51, 7308-12	8.3	52
51	Inhibition of acetylcholinesterase, beta-amyloid aggregation, and NMDA receptors in Alzheimer's disease: a promising direction for the multi-target-directed ligands gold rush. *Journal of Medicinal Chemistry*, **2008**, 51, 4381-4	8.3	170
50	Multi-target-directed ligands to combat neurodegenerative diseases. *Journal of Medicinal Chemistry*, **2008**, 51, 347-72	8.3	816
49	From dual binding site acetylcholinesterase inhibitors to multi-target-directed ligands (MTDLs): a step forward in the treatment of Alzheimer's disease. *Mini-Reviews in Medicinal Chemistry*, **2008**, 8, 960-7	3.2	48
48	Design, synthesis, and biological evaluation of pirenzepine analogs bearing a 1,2-cyclohexanediamine and perhydroquinoxaline units in exchange for the piperazine ring as antimuscarinics. *Bioorganic and Medicinal Chemistry*, **2008**, 16, 7311-20	3.4	5
47	Synthesis of a small library of 2-phenoxy-1,4-naphthoquinone and 2-phenoxy-1,4-anthraquinone derivatives bearing anti-trypanosomal and anti-leishmanial activity. *Bioorganic and Medicinal Chemistry Letters*, **2008**, 18, 2272-6	2.9	69

46	Parallel synthesis and cytotoxicity evaluation of a polyamine-quinone conjugates library. *Journal of Medicinal Chemistry*, **2008**, 51, 5463-7	8.3	29
45	Novel class of quinone-bearing polyamines as multi-target-directed ligands to combat Alzheimer's disease. *Journal of Medicinal Chemistry*, **2007**, 50, 4882-97	8.3	113
44	Insight into the kinetic of amyloid beta (1-42) peptide self-aggregation: elucidation of inhibitors' mechanism of action. *ChemBioChem*, **2007**, 8, 2152-61	3.8	289
43	A small molecule targeting the multifactorial nature of Alzheimer's disease. *Angewandte Chemie - International Edition*, **2007**, 46, 3689-92	16.4	156
42	Monolithic stationary phase coupled with coulometric detection: development of an ion-pair HPLC method for the analysis of quinone-bearing compounds. *Journal of Separation Science*, **2007**, 30, 2935-42	3.4	5
41	Recent advances in alpha1-adrenoreceptor antagonists as pharmacological tools and therapeutic agents. *Current Topics in Medicinal Chemistry*, **2007**, 7, 147-62	3	40
40	A new EGFR inhibitor induces apoptosis in colon cancer cells. *Biochemical and Biophysical Research Communications*, **2007**, 354, 409-13	3.4	21
39	Multi-target-directed drug design strategy: from a dual binding site acetylcholinesterase inhibitor to a trifunctional compound against Alzheimer's disease. *Journal of Medicinal Chemistry*, **2007**, 50, 6446-9	8.3	225
38	Recent advances in the design and synthesis of prazosin derivatives. *Expert Opinion on Drug Discovery*, **2006**, 1, 395-407	6.2	2
37	Lipoic acid, a lead structure for multi-target-directed drugs for neurodegeneration. *Mini-Reviews in Medicinal Chemistry*, **2006**, 6, 1269-74	3.2	32
36	Multitarget-directed drug design strategy: a novel molecule designed to block epidermal growth factor receptor (EGFR) and to exert proapoptotic effects. *Journal of Medicinal Chemistry*, **2006**, 49, 6642-5	8.3	70
35	Progress in acetylcholinesterase inhibitors for Alzheimer's disease. *Expert Opinion on Therapeutic Patents*, **2006**, 16, 811-823	6.8	14
34	Design, synthesis, and biological evaluation of substituted 2,3-dihydro-1H-cyclopenta[b]quinolin-9-ylamine related compounds as fructose-1,6-bisphosphatase inhibitors. *Bioorganic and Medicinal Chemistry*, **2006**, 14, 7846-53	3.4	7
33	Propidium-based polyamine ligands as potent inhibitors of acetylcholinesterase and acetylcholinesterase-induced amyloid-beta aggregation. *Journal of Medicinal Chemistry*, **2005**, 48, 24-7	8.3	127
32	Rational approach to discover multipotent anti-Alzheimer drugs. *Journal of Medicinal Chemistry*, **2005**, 48, 360-3	8.3	206
31	Heterocyclic inhibitors of AChE acylation and peripheral sites. *Il Farmaco*, **2005**, 60, 465-73		17
30	Polyamines May Modulate Both G Protein-Coupled Receptors and G Proteins. *Medicinal Chemistry Research*, **2004**, 13, 63-73	2.2	1
29	Design, synthesis, and biological evaluation of conformationally restricted rivastigmine analogues. *Journal of Medicinal Chemistry*, **2004**, 47, 5945-52	8.3	108

28	Design, synthesis and biological evaluation of ambenonium derivatives as AChE inhibitors. *Il Farmaco*, **2003**, 58, 917-28		7
27	Polymethylene tetraamine backbone as template for the development of biologically active polyamines. *Medicinal Research Reviews*, **2003**, 23, 200-33	14.4	19
26	Prazosin-related compounds. Effect of transforming the piperazinylquinazoline moiety into an aminomethyltetrahydroacridine system on the affinity for alpha1-adrenoreceptors. *Journal of Medicinal Chemistry*, **2003**, 46, 4895-903	8.3	41
25	Structure-activity relationships of methoctramine-related polyamines as muscular nicotinic receptor noncompetitive antagonists. 2. Role of polymethylene chain lengths separating amine functions and of substituents on the terminal nitrogen atoms. *Journal of Medicinal Chemistry*, **2002**, 45, 1860-78	8.3	14
24	Structure-activity relationships of methoctramine-related polyamines as muscular nicotinic receptor noncompetitive antagonists. 3. Effect of inserting the tetraamine backbone into a macrocyclic structure. *Journal of Medicinal Chemistry*, **2002**, 45, 3286-95	8.3	9
23	Analysis of the muscarinic receptor subtype mediating inhibition of the neurogenic contractions in rabbit isolated vas deferens by a series of polymethylene tetra-amines. *British Journal of Pharmacology*, **2001**, 132, 1009-16	8.6	19
22	Binding of polyamine-containing toxins in the vestibule of the nicotinic acetylcholine receptor ion channel. *Il Farmaco*, **2001**, 56, 133-5		4
21	Location of the polyamine binding site in the vestibule of the nicotinic acetylcholine receptor ion channel. *Journal of Biological Chemistry*, **2001**, 276, 6151-60	5.4	23
20	Analogues of prazosin that bear a benextramine-related polyamine backbone exhibit different antagonism toward alpha1-adrenoreceptor subtypes. *Journal of Medicinal Chemistry*, **2001**, 44, 362-71	8.3	12
19	Design, synthesis, and biological activity of methoctramine-related polyamines as putative G(i) protein activators. *Journal of Medicinal Chemistry*, **2001**, 44, 4035-8	8.3	9
18	Hexahydrochromeno[4,3-b]pyrrole derivatives as acetylcholinesterase inhibitors. *Journal of Medicinal Chemistry*, **2001**, 44, 105-9	8.3	24
17	Structure-activity relationship and site of binding of polyamine derivatives at the nicotinic acetylcholine receptor. *FEBS Journal*, **2000**, 267, 110-20		28
16	[4-[[N-(3-chlorophenyl)carbamoyl]oxy]-2-butynyl]-trimethylammonium (McN-A-343)-related compounds. Effect of the butynyl chain inclusion into an aromatic unit on the potency for muscarinic receptors. *Bioorganic and Medicinal Chemistry*, **2000**, 8, 681-9	3.4	2
15	Prejunctional muscarinic inhibitory control of acetylcholine release in the human isolated detrusor: involvement of the M4 receptor subtype. *British Journal of Pharmacology*, **2000**, 129, 493-500	8.6	63
14	Design, synthesis, and biological evaluation of symmetrically and unsymmetrically substituted methoctramine-related polyamines as muscular nicotinic receptor noncompetitive antagonists. *Journal of Medicinal Chemistry*, **1999**, 42, 5212-23	8.3	37
13	WB 4101-related compounds. 2. Role of the ethylene chain separating amine and phenoxy units on the affinity for alpha(1)-adrenoreceptor subtypes and 5-HT(1A) receptors. *Journal of Medicinal Chemistry*, **1999**, 42, 4214-24	8.3	26
12	Search for selective antagonists at alpha 1-adrenoreceptors: neutral or negative antagonism?. *Il Farmaco*, **1998**, 53, 278-86		17
11	Acetylcholinesterase noncovalent inhibitors based on a polyamine backbone for potential use against Alzheimer's disease. *Journal of Medicinal Chemistry*, **1998**, 41, 4186-9	8.3	73

10	Universal template approach to drug design: polyamines as selective muscarinic receptor antagonists. *Journal of Medicinal Chemistry*, **1998**, 41, 4150-60	8.3	32
9	Design, synthesis, and biological activity of prazosin-related antagonists. Role of the piperazine and furan units of prazosin on the selectivity for alpha1-adrenoreceptor subtypes. *Journal of Medicinal Chemistry*, **1998**, 41, 4844-53	8.3	25
8	Opioid antagonist activity of naltrexone-derived bivalent ligands: importance of a properly oriented molecular scaffold to guide "address" recognition at kappa opioid receptors. *Journal of Medicinal Chemistry*, **1996**, 39, 1816-22	8.3	15
7	Synthesis, muscarinic blocking activity and molecular modeling studies of 4-DAMP-related compounds. *Bioorganic and Medicinal Chemistry*, **1995**, 3, 267-77	3.4	8
6	In vitro characterization of tripitramine, a polymethylene tetraamine displaying high selectivity and affinity for muscarinic M2 receptors. *British Journal of Pharmacology*, **1995**, 114, 1507-17	8.6	29
5	Binding profile of the selective muscarinic receptor antagonist tripitramine. *European Journal of Pharmacology*, **1994**, 268, 459-62		44
4	Binding profile of benextramine at neuropeptide Y receptor subtypes in rat brain areas. *European Journal of Pharmacology*, **1994**, 265, 93-8	5.3	11
3	Design, synthesis, and biological activity of methoctramine-related tetraamines bearing an 11-acetyl-5,11-dihydro-6H-pyrido[2,3-b][1,4] benzodiazepin-6-one moiety: structural requirements for optimum occupancy of muscarinic receptor subtypes as revealed by symmetrical and	8.3	24
2	Synthesis and biological activity of some methoctramine-related tetraamines bearing a 11-acetyl-5,11-dihydro-6H-pyrido[2,3-b][1,4]-benzodiazepin-6-one moiety as antimuscarinics: a second generation of highly selective M2 muscarinic receptor antagonists. *Journal of Medicinal Chemistry*, **1993**, 36, 3734-7	8.3	41
1	Multitarget Drug Discovery1-7		